Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Organ Failure | 15 | 2021 | 177 | 3.820 |
Why?
|
| Plasma Exchange | 11 | 2024 | 117 | 2.440 |
Why?
|
| Sepsis | 15 | 2024 | 652 | 2.170 |
Why?
|
| Disseminated Intravascular Coagulation | 6 | 2020 | 106 | 1.730 |
Why?
|
| ADAM Proteins | 6 | 2023 | 134 | 1.300 |
Why?
|
| von Willebrand Factor | 10 | 2023 | 335 | 1.270 |
Why?
|
| Thrombocytopenia | 7 | 2020 | 846 | 1.210 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 5 | 2021 | 184 | 1.030 |
Why?
|
| Shock, Septic | 7 | 2020 | 181 | 0.820 |
Why?
|
| Thrombosis | 6 | 2022 | 781 | 0.810 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2020 | 69 | 0.750 |
Why?
|
| Critical Care | 9 | 2021 | 770 | 0.750 |
Why?
|
| Critical Illness | 10 | 2024 | 714 | 0.740 |
Why?
|
| Endotoxemia | 2 | 2023 | 61 | 0.720 |
Why?
|
| Plasmapheresis | 2 | 2012 | 61 | 0.690 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 61 | 0.650 |
Why?
|
| ADAMTS13 Protein | 7 | 2023 | 92 | 0.630 |
Why?
|
| Pediatrics | 7 | 2020 | 1141 | 0.590 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2015 | 110 | 0.580 |
Why?
|
| Hemodynamics | 6 | 2020 | 935 | 0.570 |
Why?
|
| Life Support Systems | 1 | 2015 | 5 | 0.530 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2014 | 16 | 0.490 |
Why?
|
| Factor Xa | 1 | 2014 | 26 | 0.480 |
Why?
|
| Partial Thromboplastin Time | 1 | 2014 | 55 | 0.480 |
Why?
|
| Liver Diseases | 1 | 2018 | 574 | 0.450 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 577 | 0.450 |
Why?
|
| Blood Coagulation Disorders | 2 | 2013 | 120 | 0.420 |
Why?
|
| Liver Transplantation | 4 | 2023 | 1112 | 0.420 |
Why?
|
| Drug Monitoring | 1 | 2014 | 333 | 0.410 |
Why?
|
| Heparin | 1 | 2014 | 360 | 0.400 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2017 | 581 | 0.400 |
Why?
|
| Coinfection | 1 | 2012 | 189 | 0.380 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 242 | 0.370 |
Why?
|
| Intensive Care Units, Pediatric | 6 | 2019 | 441 | 0.370 |
Why?
|
| Infant | 22 | 2023 | 13310 | 0.360 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2011 | 70 | 0.360 |
Why?
|
| Ferritins | 2 | 2021 | 151 | 0.340 |
Why?
|
| Peptide Fragments | 1 | 2015 | 1271 | 0.340 |
Why?
|
| Child | 26 | 2023 | 29154 | 0.340 |
Why?
|
| Child, Preschool | 20 | 2021 | 16273 | 0.340 |
Why?
|
| Anticoagulants | 2 | 2014 | 787 | 0.330 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 548 | 0.330 |
Why?
|
| Biliary Atresia | 2 | 2023 | 191 | 0.320 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 739 | 0.310 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 383 | 0.310 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 672 | 0.290 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 610 | 0.260 |
Why?
|
| Influenza, Human | 1 | 2012 | 925 | 0.260 |
Why?
|
| Resuscitation | 4 | 2020 | 223 | 0.240 |
Why?
|
| Humans | 47 | 2024 | 261506 | 0.230 |
Why?
|
| Fibrin | 3 | 2022 | 82 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2403 | 0.220 |
Why?
|
| Platelet Adhesiveness | 2 | 2015 | 57 | 0.210 |
Why?
|
| HLA-DR Antigens | 1 | 2021 | 173 | 0.200 |
Why?
|
| Biomarkers | 5 | 2017 | 5047 | 0.200 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2021 | 141 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2022 | 155 | 0.190 |
Why?
|
| Macrophage Activation Syndrome | 2 | 2017 | 11 | 0.190 |
Why?
|
| Adolescent | 13 | 2021 | 31252 | 0.190 |
Why?
|
| Hydrolases | 1 | 2021 | 123 | 0.180 |
Why?
|
| Extracorporeal Circulation | 2 | 2018 | 43 | 0.180 |
Why?
|
| Liver Cirrhosis | 3 | 2023 | 941 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 170 | 0.170 |
Why?
|
| Thromboplastin | 2 | 2016 | 34 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2021 | 243 | 0.170 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 1073 | 0.160 |
Why?
|
| Lipopolysaccharides | 2 | 2023 | 558 | 0.160 |
Why?
|
| Male | 19 | 2023 | 123000 | 0.150 |
Why?
|
| Arginine | 1 | 2021 | 500 | 0.150 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 59 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2021 | 451 | 0.150 |
Why?
|
| Phenotype | 2 | 2020 | 6295 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 615 | 0.150 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 30 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 135 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 1688 | 0.140 |
Why?
|
| Female | 18 | 2023 | 141928 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 354 | 0.140 |
Why?
|
| Shiga Toxins | 1 | 2015 | 5 | 0.140 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 200 | 0.140 |
Why?
|
| Complement Inactivating Agents | 1 | 2015 | 16 | 0.130 |
Why?
|
| Organ Dysfunction Scores | 3 | 2020 | 66 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 384 | 0.130 |
Why?
|
| Endothelium | 1 | 2016 | 158 | 0.130 |
Why?
|
| Cause of Death | 1 | 2018 | 752 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 4053 | 0.130 |
Why?
|
| Hemostasis | 1 | 2016 | 109 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 3 | 2020 | 151 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2023 | 1048 | 0.130 |
Why?
|
| Complement System Proteins | 1 | 2015 | 139 | 0.130 |
Why?
|
| Infant, Newborn | 7 | 2021 | 8223 | 0.120 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2014 | 79 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 2927 | 0.120 |
Why?
|
| Fluid Therapy | 3 | 2020 | 182 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 1586 | 0.120 |
Why?
|
| Blood Coagulation Tests | 1 | 2013 | 87 | 0.110 |
Why?
|
| Retrospective Studies | 10 | 2024 | 37905 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 423 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2021 | 6100 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.110 |
Why?
|
| Medical Audit | 1 | 2012 | 188 | 0.100 |
Why?
|
| Risk Factors | 4 | 2023 | 17523 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 1085 | 0.100 |
Why?
|
| Catheterization, Peripheral | 1 | 2013 | 158 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2016 | 6869 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2016 | 1171 | 0.090 |
Why?
|
| Mitochondria | 1 | 2017 | 1282 | 0.090 |
Why?
|
| Disease Progression | 2 | 2018 | 6682 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2013 | 330 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 6942 | 0.090 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 100 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2013 | 712 | 0.080 |
Why?
|
| Protein Binding | 1 | 2015 | 3438 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2013 | 717 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 1697 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 65 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 1099 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 4320 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 5539 | 0.070 |
Why?
|
| Glutathione | 1 | 2008 | 368 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 980 | 0.070 |
Why?
|
| United States | 5 | 2017 | 15433 | 0.070 |
Why?
|
| Protein C | 1 | 2006 | 32 | 0.070 |
Why?
|
| Animals | 8 | 2023 | 59536 | 0.070 |
Why?
|
| Child Mortality | 1 | 2005 | 21 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2012 | 1335 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 1008 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 2594 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 4744 | 0.070 |
Why?
|
| Consensus | 2 | 2020 | 978 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 7222 | 0.070 |
Why?
|
| Infant Mortality | 1 | 2005 | 186 | 0.060 |
Why?
|
| Prognosis | 4 | 2017 | 21713 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2005 | 137 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2021 | 1144 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 2307 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 3251 | 0.060 |
Why?
|
| Medical Order Entry Systems | 1 | 2005 | 125 | 0.060 |
Why?
|
| Platelet Count | 2 | 2016 | 490 | 0.060 |
Why?
|
| Propofol | 1 | 2003 | 80 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1559 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 1351 | 0.050 |
Why?
|
| Hospital Mortality | 3 | 2017 | 1274 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 34495 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1038 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2022 | 63 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 218 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 321 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 2422 | 0.050 |
Why?
|
| Logistic Models | 1 | 2008 | 3441 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 246 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 12221 | 0.050 |
Why?
|
| Biological Availability | 1 | 2021 | 214 | 0.050 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 164 | 0.050 |
Why?
|
| Fibrinogen | 2 | 2013 | 205 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 182 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2021 | 171 | 0.050 |
Why?
|
| Citrulline | 1 | 2021 | 108 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2021 | 875 | 0.040 |
Why?
|
| Age Factors | 1 | 2008 | 5377 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 12926 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 32848 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 4892 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 305 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 98 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 2049 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 561 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 344 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2020 | 465 | 0.040 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2016 | 19 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 2016 | 63 | 0.040 |
Why?
|
| Granzymes | 1 | 2016 | 91 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 1541 | 0.040 |
Why?
|
| Glycocalyx | 1 | 2016 | 4 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 422 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2016 | 161 | 0.030 |
Why?
|
| Algorithms | 2 | 2020 | 3890 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 128 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 446 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2014 | 47 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8865 | 0.030 |
Why?
|
| beta-Glucans | 1 | 2014 | 34 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2014 | 63 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 699 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 519 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 77950 | 0.030 |
Why?
|
| Fungemia | 1 | 2014 | 116 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2014 | 146 | 0.030 |
Why?
|
| Granulocytes | 1 | 2014 | 224 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2014 | 172 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 502 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 259 | 0.030 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 8 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 296 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 2013 | 44 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 14889 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 68 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1182 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 12873 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 223 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 173 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 1544 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1900 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4314 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 644 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 700 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 21445 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 2074 | 0.020 |
Why?
|
| Inflammation | 1 | 2020 | 2522 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 9180 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Antigens, Human Platelet | 1 | 2008 | 5 | 0.020 |
Why?
|
| Glutathione Disulfide | 1 | 2008 | 20 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2010 | 240 | 0.020 |
Why?
|
| Hemorheology | 1 | 2008 | 45 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5673 | 0.020 |
Why?
|
| Integrin beta3 | 1 | 2008 | 44 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 2283 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 205 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 717 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 311 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 131 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 1375 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2016 | 1154 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 311 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 706 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2007 | 115 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2992 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 717 | 0.020 |
Why?
|
| Microcirculation | 1 | 2007 | 200 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 9244 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 842 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 4971 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1618 | 0.020 |
Why?
|
| Contraindications | 1 | 2003 | 150 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 2944 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 891 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 332 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 465 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2003 | 448 | 0.010 |
Why?
|